Advice
following a full submission:
apixaban (Eliquis®) is accepted for use within NHS Scotland.
Indication under review: for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ≥II).
Apixaban was superior to standard oral anticoagulation at preventing stroke or systemic embolism in one large, double-blind study in patients with atrial fibrillation and at least one risk factor for stroke. It was also associated with a significant reduction in risk of major bleeding.
Download detailed advice302KB (PDF)
Medicine details
- Medicine name:
- apixaban (Eliquis)
- SMC ID:
- 836/13
- Indication:
- For the prevention of stroke and systemic embolism (SE) in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors such as prior stroke or transient ischaemic attack(TIA): age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYYA Class ≥ II).
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 February 2013